O f the eight biological DMARDs licensed for the treatment of rheu matoid arthritis, five act by inhibiting TNF alpha (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), one modulates the activity of T cells (abata cept), one depletes B cells (rituximab) and one (tocilizumab) inhibits the activ ity of interleukin6 (IL6). All have been recommended by NICE for severe active disease in patients whose disease is not controlled using conventional DMARDs. 1, 2 Sarilumab (Kevzara) is a recombi nant human monoclonal antibody. Like tocilizumab, it binds to soluble and mem branebound IL6 receptors and inhibits IL6mediated signalling. The proinflam matory cytokine IL6 is produced by several cell types and, like TNF alpha, appears to have multiple roles in the pathogenesis of rheumatoid arthritis.
Indications and dosage
Sarilumab is licensed, in combination with methotrexate, for the treatment of moderately to severely active rheumatoid arthritis in adults who have responded inadequately to or who are intolerant to one or more DMARDs; and as monother apy when methotrexate is not tolerated or not appropriate.
Sarilumab is administered as a sub cutaneous injection of 200mg once every two weeks, reducing to 150mg every two weeks if neutropenia, thrombocytopenia or liver enzyme elevation occur. Treatment should not be initiated in patients with serious infection, or those with low neutrophil or platelet counts. No dose adjustment is recommended for elderly people or in patients with mild to moder ate renal impairment. Sarilumab has not been evaluated in patients with hepatic impairment or severe renal impairment.
NICE has now recommended sari lumab in combination with methotrexate, as an option for severe active rheuma toid arthritis in adults whose disease has responded inadequately to inten sive therapy with a combination of con ventional DMARDs. 3 Severe disease is defined as a disease activity score (DAS28) of more than 5.1. Sarilumab is also recommended with methotrexate in adults with severe active disease who have responded inadequately to, or who cannot take, other DMARDs, including at least one biological DMARD, and who cannot take rituximab. NICE adds that sarilumab can be used as monotherapy in patients who cannot take methotrex ate because of a contraindication or intol erance. Treatment should be continued only if there is at least a moderate response, as measured using the European League Against Rheumatism (EULAR) criteria at six months after starting therapy, or if the response to therapy is not maintained.
Clinical trials
Three phase 3 trials provide the key data for sarilumab. 46 The MOBILITY trial ran domised 1197 patients with moderate to severe active rheumatoid arthritis despite treatment with methotrexate to receive methotrexate plus sarilumab 150mg or 200mg fortnightly or methotrexate plus placebo. 4 Patients who had previously not responded to treatment with a biolog ical DMARD were excluded. The primary endpoints were the ACR20 response (the proportion of patients meeting American College of Rheumatology criteria for 20% improvement in disease activity) after 24 weeks; change in physical function measured by the Health Assessment Questionnaire disability index after 16 weeks; and change in radiographic joint damage at week 52.
Mean duration of rheumatoid arthritis was about nine years and mean disease activity score (DAS28) was approximately 6.0. Compared with methotrexate plus placebo, methotrexate plus sarilumab significantly increased the proportion of patients with ACR20 response at 24 weeks (66% and 58% with 200mg and 150mg sarilumab vs 33% with placebo; p<0.0001). Though responses were slightly diminished after 52 weeks (see Figure 1 ), treatment was associated with a significant improvement in phys ical activity and a significant reduction in radiographic progression (proportions with no progression at 52 weeks were 56% and 48% with 200mg and 150mg sarilumab vs 39% with placebo).
In TARGET, 5 546 patients with moder ate to severe active rheumatoid arthritis after inadequate response or intoler ance to TNF inhibitor therapy were ran domised to receive sarilumab 150mg, sarilumab 200mg or placebo combined with conventional DMARD therapy (85% methotrexate). The primary endpoints were ACR20 response at 24 weeks and change in disability index after 12 weeks.
Mean duration of rheumatoid arthritis was about 12 years and mean DAS28 score was 6.2. More patients treated with sarilumab met ACR20 response criteria (61% and 56% with 200mg and 150mg vs 34% with placebo; p<0.0001) and disability index improved significantly with both doses compared with placebo. The MONARCH trial compared mono therapy with sarilumab 200mg or adal imumab 40mg, both given every two weeks, in 369 patients with moderate to severe active rheumatoid arthritis for whom methotrexate was discontin ued due to intolerance or inadequate response. 6 The primary efficacy endpoint was change in DAS28 at week 24 (in this study, DAS28 was assessed using the erythrocyte sedimentation rate [DAS28 ESR], which yields a higher score than when Creactive protein (CRP) is used, as was the case in MOBILITY and TARGET).
Mean duration of rheumatoid was lower in patients assigned to adali mumab (6.6 vs 8.1 years); mean DAS28 ESR score was 6.8 (mean DAS28CRP score was 6.0). About 55% of patients had previously stopped methotrexate due to inadequate effectiveness and 45% due to intolerance. Fewer patients assigned to sarilumab discontinued treatment (10% vs 15% with adalimumab). After 24 weeks, the reduction in DAS28ESR was significantly greater with sarilumab than adalimumab (3.28 vs 2.20; p<0.0001) (see Figure 2 ) and more patients were in remission (DAS28 ESR <2.6) by this measure (27% vs 7.0%; p<0.0001). This was matched by changes in DAS28CRP . The 24week ACR20 response, a secondary endpoint, was significantly greater with sarilumab (72% vs 58%, p=0.0074).
Adverse effects
Treatment with sarilumab is associated with increased incidence of infections (including serious infections), neutro penia, thrombocytopenia, elevated transaminases, dyslipidaemia and injec tionsite reactions. In the MONARCH trial, adverse events more frequently associ ated with sarilumab than adalimumab included neutropenia (14% vs 0.5%) and injectionsite erythema (7.6% vs 3.3%) but dyslipidaemia was less frequent (1.6% vs 4.3%); the frequencies of seri ous infections were similar. 6 
